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Abstract
Warfarin is used in paediatric populations, but dosing algorithms incorporating pharmacogenetic 
data have not been developed for children. Previous studies have produced estimates of the effect 
of polymorphisms in CYP2C9 and VKORC1 on stable warfarin dosing, but data on time in 
therapeutic range, initial dosing and adverse effects are limited. Participants (n=97) were recruited, 
and routine clinical data and salivary DNA samples were collected from all participants, and 
analysed for CYP2C9*2, *3 and VKORC1-1639 polymorphisms.VKORC1 -1639 was associated 
with a greater proportion of the first six months’ treatment time spent within the target INR range, 
accounting for an additional 9.5% of the variance in the proportion of time. CYP2C9*2 was 
associated with a greater likelihood of INR values exceeding the target range during the initiation 
of treatment (OR [per additional copy] 4.18, 95% CI 1.42, 12.34). CYP2C9*2 and VKORC1-1639 
were associated with a lower dose requirement, and accounted for almost 12% of the variance in 
stable dose. VKORC1-1639 was associated with an increased likelihood of mild bleeding 
complications (OR [heterozygotes vs homozygotes] 4.53, 95% CI 1.59, 12.93). These data show 
novel associations between VKORC1-1639 and CYP2C9*2 and INR values in children taking 
warfarin, as well as replicating previous findings with regard to stable dose requirements. The 
development of pharmacogenomic dosing algorithms for children using warfarin has the potential 
to improve clinical care in this population.
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Introduction
Warfarin, a synthetic coumarin used for anticoagulation, has a narrow therapeutic index and 
exhibits wide inter-individual variation in the maintenance dose required (0.5 mg/day to 20 
mg/day). Proportionally, far fewer children are treated with warfarin than adults. Indications 
for paediatric use include treatment of thromboembolic disorders, prophylaxis for heart 
valve replacement, following cavopulmonary shunts and completion of the Fontan 
circulation in patients with complex congenital heart disease 1. Warfarin requires regular 
therapeutic monitoring through the use of the International Normalised Ratio (INR). The 
INR required for successful anticoagulation varies by indication for anticoagulation 
(Supplementary Data Table 1), following national recommendations 2.
The pharmacokinetics and pharmacodynamics of warfarin in the young differ both from 
adults 1, 3, 4, and across childhood3, 5, 6. Within children, dose requirements have been 
shown to be affected by weight (directly associated), and age (inversely associated)3, 5-7. 
Drug interactions also contribute to dose variation5.
Polymorphisms in 2 genes, vitamin K epoxide reductase complex subunit 1 (VKORC1) and 
Cytochrome P450 2C9 (CYP2C9), in combination with environmental factors, have a 
significant effect on warfarin dosing in adults 8-10. Adult patients from a variety of ethnic 
backgrounds with the variant allele(s) in one of the recognised polymorphisms in the 
VKORC1 gene (rs9923231, VKORC1-1639), and/or a variant allele(s) in polymorphisms in 
the CYP2C9 gene (rs1057910 and rs1799853, CYP2C9*2 and *3 respectively) require lower 
doses of warfarin 9, 11-18. In adults, up to 30% of the dose variation can be explained by 
these 2 genetic factors 19, increasing to between 31.4 and 58.7% when clinical factors 
(including age, sex, drug interactions, ethnicity, BMI, etc.) are incorporated 19. Dosing 
algorithms that incorporate this pharmacogenetic data have been developed for adult 
patients 9, 20 and shown to be more effective than standard dosing when using an initial 
loading dose strategy 21.
Dosing algorithms have also been published for paediatric populations. Pharmacogenetic 
information is not included 3, 6, 22, 23, but paediatric haematologists are interested in updated 
algorithms including genetic factors 24. In children, the stable dose requirement is related to 
age, as well as patient height, genetic polymorphisms in VKORC1 and CYP2C9, and 
indication for warfarin 25-27. The effect estimates for stable dose vary considerably between 
publications, both for genetic factors [the estimates of VKORC1, contribution to warfarin 
stable dose requirements in children varies between 3.7-26.6%, for CYP2C9 0.4-12.8%], and 
total explained variability (38-72%) 25-27.
However, previous studies have not found a relationship between the time spent within INR 
range 26 and time to therapeutic range 27 and either CYP2C9 or VKORC1 polymorphisms. 
There are data suggesting a relationship between these genetic factors and INR exceeding 
the target range in the first week of therapy 28, but they have not been replicated, and there is 
no data on the risk of haemorrhage.
The aims of this study were therefore to examine the association between genetic (VKORC1 
and CYP2C9) and non-genetic factors and stable maintenance dosing, and quantify the 
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proportion of variability explained by these factors. We also aimed to examine the 
association between these genetic polymorphisms and time within therapeutic INR range, an 
INR above the recommended range in the first week of use, and haemorrhage.
Methods
Study design
This retrospective cohort study received full ethical approval (North West 3 Research Ethics 
Committee). Participants were recruited between November 2009 and January 2011. 
Eligibility criteria: warfarin prescribed for ≥ 3 months; age ≤ 18 years; therapeutic drug 
monitoring of INR undertaken by Alder Hey Children’s Hospital, UK, a tertiary referral 
centre; and written informed consent received from parent (participant age < 16 years) or 
participant (if age ≥ 16 years). Participant assent was sought from children and young people 
(each child assessed individually for level of understanding). Refusal of assent by a young 
person with good understanding of the study was an exclusion criterion.
The majority of children in Alder Hey Children’s hospital on warfarin are cared for in the 
community, using point of care (POC) INR testing. Management of children receiving 
warfarin using POC testing has been shown to be a safe and effective alternative to testing 
of INRs in clinic 29. Patients and families inform the cardiac liaison nurse team about the 
INRs and dose adjustment’s carried out 30, and all this data are recorded electronically. All 
data (INR, dose, clinical variables) were collected retrospectively from the cardiac liaison 
team electronic database and medical records, from the date of initiation of warfarin therapy 
to the date of recruitment. The current recommended levels of anticoagulation for children at 
Alder Hey children’s hospital are derived from British Society of Haematology guidelines 
(Supplementary Data Table 1) 2.
Data collection
Warfarin dose and INR values for each POC testing event is routinely collected for all 
patients using warfarin at our institution, and this data were extracted onto our study 
database. From this information, each patient’s full dose and INR history could be 
determined.
Data were also collected on indication for treatment, target INR, age, gender, height, weight, 
BMI, haemorrhagic complications, serial serum albumin concentration(s) (as many children 
were hypoalbuminaemic at onset of therapy), and height and weight measurements. Clinical 
data were collected from hospital notes and the cardiac liaison team database.
All variables were checked for completeness and accuracy. Where missing data were noted, 
an attempt was made to retrieve these data. To check data accuracy, range and consistency 
checks were undertaken.
DNA collection and extraction, and Genotyping
Genotyping of CYP2C9*2 (rs 1799853), CYP2C9*3 (rs 1057910) and VKORC1-1639 (rs 
9923231) was undertaken. Full details are given in the online supplementary data section.
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Outcomes
Study outcomes were as pre-specified in the protocol, as follows:
Primary outcome variable
• The proportion of time in which INR measurements fell within the target range 
(PTIR) within the first six months. Linear interpolation 31 was used to estimate the 
proportion of time patients spent in therapeutic range between two test days.
Secondary outcome measures
• INR exceeding the target range within the first week of treatment (Yes/No);
• Stable dose (mg/day), defined as the mean daily dose required to achieve three 
consecutive INR measurements within the individual’s target range over a 
minimum period of four weeks, at the same daily dose;
• Haemorrhagic complications: classified according to the methods of both Fihn et 
al. and Streif et al. 5, 32
Statistical analysis
All analyses were performed in R version 2.13 33. The following quality control (QC) for 
each single nucleotide polymorphism (SNP) was undertaken prior to analyses of association: 
checks for Hardy-Weinberg equilibrium (p <0.01 indicated deviation); checks for 
missingness per sample (excluded if >5% missing); checks for missingness per SNP 
(excluded if >5% missing); checks for SNP minor allele frequency (MAF) (exclude if MAF 
<1%).
For the purpose of calculating the outcome of stable dose, where a patient was on a dosing 
regimen that required different doses to be taken on different weekdays, the daily warfarin 
dose was taken as the average dose over a week (e.g. if a patient takes 2mg for 2 consecutive 
days then 3mg on the third day, the average weekly dose is 16mg, and therefore the mean 
daily dose was calculated as 2.3mg). For the purpose of estimating the INR value for a day 
that fell between two test days, the method of linear interpolation 34 was used.
In terms of tests of association, first, non-genetic variables (age, gender, height, weight, 
BMI, albumin, target INR group indication for treatment, and haemorrhagic complications), 
specified a priori as being of potential importance, were each individually tested for 
association with each outcome. Patients were grouped according to their target INR range, 
with groups based on the lower limit of the target INR range (rounded to the nearest 0.5).
Two different classifications for indication for treatment were used: two-group, in which 
patients were divided into non-Fontans and Fontans groups; or three-group, in which 
patients were divided into non-Fontans cardiac, Fontans cardiac and non-cardiac groups. For 
the primary outcome and the outcome of INR exceeding target range during the first week, 
values of these variables at the start of warfarin treatment were referred to. For the outcome 
of stable dose, values of these variables at the time stability was achieved were referred to. 
For the outcome of haemorrhagic complications, no tests for association with non-genetic 
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variables were undertaken, since it was not possible to determine what time point should be 
referred to for obtaining the value of these variables in those not experiencing an event.
For some of the non-genetic variables there was a considerable amount of missing data (see 
Table 1). In order to minimise the impact of this, multiple imputation using chained 
equations 34, specifically the predictive mean matching method, was used to impute data for 
height, weight and albumin at the start of warfarin treatment (all variables had <30% 
missing observations). Multiple imputation was not used for these variables at the time 
stable dose was achieved, as the amount of missingness was deemed too high (>40%). 
Instead, these variables were excluded from the list of potential covariates.
To test for association with each individual SNP, two regression models were fitted. The 
first (the ‘baseline model’) included all non-genetic factors giving a p-value < 0.10 
univariately and the second (the ‘genetic model’) was the same as the first but also included 
covariates to represent the SNP.
Both models were compared using the likelihood ratio test. Two analyses were carried out 
for each SNP: one with no underlying assumptions regarding the mode of inheritance (i.e. 
using two variables to represent the SNP – one representing heterozygotes, one representing 
mutant homozygotes) and another assuming an additive mode of inheritance (i.e. using a 
single variable to represent the SNP, with heterozyotes coded ‘1’ and mutant homozygotes 
coded ‘2’). Due to the multiple tests of association, the false discovery rate (FDR) 
controlling procedure was used, with an overall error rate of 5% 35. For the outcome of 
haemorrhagic complications and any outcome where none of the non-genetic variables were 
significant univariately, the baseline model was the null model, since it did not include any 
variables.
Finally, to investigate the total amount of variation explained by non-genetic and genetic 
factors combined, a multiple regression model was fitted for each outcome. Covariates 
included non-genetic factors giving p < 0.10 univariately as well as SNPs that were 
significant under FDR control. For continuous variables, multiple linear regression was 
performed and the adjusted R2 value was recorded. For binary variables, logistic regression 
was performed and pseudo R2 values calculated
Results
Participant characteristics
Participant characteristics are provided in Table 1. A total of 100 patients were recruited 
(Male n=55), all of whom took warfarin for ≥6 months. Ethnicity of the patients was 
reported as European Caucasian (n=97), Black (n=1), Indian (n=1) and Afghan (n=1). 
Further analyses were restricted to the 97 European Caucasians - 85 of these were 
anticoagulated following surgery for congenital heart disease (Fontan’s procedure n=62; 
other cardiac procedures n=23) and 12 were non-cardiac patients. The lower limit of the 
target INR range (rounded to the nearest 0.5) was 1.5 in 3 patients, 2.0 in 71 patients, 2.5 in 
8 patients and 3.0 in 15 patients. The genotype frequencies of the patients were: CYP2C9*2 
76 (78.4%), 19 (19.6%) and 2 (2.1%) (Homozygous wildtype, heterozygote, homozygote 
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variant respectively); CYP2C9*3 79 (81.4%), 18 (18.6%), and 0 (0%); VKORC1-1639 40 
(41.2%), 45 (46.4%), and 12 (12.4%). Genotype combinations are shown in supplementary 
table 3. All three SNPs were in Hardy-Weinberg equilibrium (p > 0.60).
Outcome data
The mean PTIR in the first six months of treatment was 0.50 (SD 0.27) and the mean stable 
warfarin dose was 2.70 (SD 1.65) mg/day. Thirty-nine (40.2%) patients had an INR above 
range in the first week, 49 (50.5%) did not, and insufficient data were available to determine 
this in nine (9.3%) patients. There were no reported major (Streif classification5), or severe 
(or greater) (Fihn Classification32) haemorrhagic complications. Sixty-nine (71.1%) patients 
experienced minor (Fihn classification32) or mild (Streif classification5 bleeds. A chi-square 
analysis between INR≥4 in week one and minor/mild bleeding did not show a significant 
association (p=0.19).
Analyses of association with each non-genetic variable
Data regarding associations between the non-genetic factors and outcome variables (with the 
exception of the haemorrhagic complications outcome) are shown in Table 3. It was not 
possible to test for association between height, weight, BMI or albumin levels and stable 
dose due to the significant amount of missing observations for these variables at the time 
stable dose was achieved. Target INR group and indication for treatment were both 
associated with proportion time in INR range during the first six months (p<0.10), and were 
therefore adjusted for in the SNP-association analyses with this outcome. None of the non-
genetic variables were associated with the outcome of INR exceeding target range during the 
first week,whilst age and target INR group were associated with stable dose (p<0.10).
Analyses of association with each SNP
Results from undertaking likelihood-ratio tests comparing the baseline model to the genetic 
model for each outcome are provided in Table 3. As analyses were undertaken both without 
any assumptions regarding the underlying mode of inheritance and assuming an additive 
mode, only the lowest p-value is reported. SNPs that remained significant under FDR 
control were entered into the final multiple regression models (Table 4).
Multiple regression models
The R2 values for multiple regression models built for each outcome, including the non-
genetic variables with p <0.10 and genetic variables significant under FDR control, are 
provided in Table 4.
Together, the indication for treatment and target INR groupings accounted for 
approximately 11% of the variance in the PTIR during the first six. The presence of the 
variant allele VKORC1-1639 was associated with a greater time spent within range, with 
each additional variant allele associated with approximately 13% (95% CI 5% to 21%) more 
time spent within the target INR range in the first six months. VKORC1-1639 combined with 
the aforementioned non-genetic factors explained almost 21% variability in proportion of 
the first six months’ treatment time spent within the target INR range. Genetic data related 
to proportion of time INR within target range is shown in Figure 1. Patients heterozygous 
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for CYP2C9*2 were approximately four times as likely, and mutant homozygotes around 17 
times as likely, to have INR values exceeding the target range in the first week as wild-type 
homozygous patients.
Overall, the patient’s age, target INR range and genotypes at CYP2C9*2 and VKORC1-1639 
accounted for approximately 41% of the variability in the warfarin dose required to stabilise 
INR. The presence of the variant alleles, CYP2C9*2 and VKORC1-1639, was associated 
with a lower dose required to stabilise INR, with CYP2C9*2 variant alleles associated with 
an approximate decrease in daily dose of 0.82 mg and VKORC1-1639 variant alleles 
associated with an approximate decrease of 0.66 mg. Based on the change in adjusted R2 
values with the addition of the genetic variables, VKORC1-1639 accounted for 
approximately 7% and CYP2C9*2 approximately 5% of the overall variance in stable dose.
The presence of one variant allele at VKORC1-1639 was associated with an increased 
likelihood of haemorrhagic complications, with heteroygotes having approximately 4.5 
times the likelihood of a bleeding event as wild-type homozygotes. No significant 
association was found between having two copies of the mutant allele and haemorrhagic 
complications largely because these individuals were rare and we had insufficient power to 
detect an association.
Discussion
Many significant pharmacogenomic associations do not make clinical impact due to lack of 
replication. We are therefore pleased to report that these data replicate previous publications 
showing that VKORC1-1639 and CYP2C9*2 both result in decreased stable warfarin dose 
requirements. The estimates of R2 for daily dose requirement that we have derived for these 
variant alleles suggests that VKORC1-1639 and CYP2C9*2 contribute 7% and 5% 
respectively. Previously published R2 values for the effect of VKORC1-1639 on stable 
warfarin dose requirements have produced values of 3.7% 27, 18.2% 26 and 26.6% 25, 
putting our value of 7% at the lower end of the range. The R2 values previously published 
for the effects of mutant alleles of CYP2C9 on stable warfarin dose were 0.4% 27, 2.0 26 and 
12.8% 25, and again our value of 5% is consistent. The total variability in stable warfarin 
dosing explained by the genetic factors above, as well as target INR range and age, in our 
cohort is 41.4%. This is similar to Nowak-Göttl et al. (38%), but lower than Biss et al. 
(72.4%) and Moreau et al. (69.7%). Possible reasons for the difference include the age of the 
children studied (younger than in previous studies) and the concomitant use of age as a 
surrogate for height/weight. Fifty-four percent of our study cohort were less than 6 years old 
when stable dose was reached, compared to 23% in the cohort studied by Biss et al 25. 
Similarly, in the study by Moreau et al.26 the mean age was 8.4 years (± 5.6) while in this 
study, it was 6.9 (± 4.5) years. It is possible that genetic factors may become more important 
as the child grows older and would be consistent with the increased expression of CYP2C9 
seen through gestation and childhood 36. An alternative approach would be to conduct a 
meta-analysis of stable doses of warfarin in children which was considered by us. However, 
in the six previously published studies, there was a lack of reporting of key data (including 
mean dose and standard deviation per genotype group). Indeed, the only meta-analysis 
possible would have been limited to a single polymorphism (VKORC1-1639) and included 
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only two out of the six studies, and so would not significantly have improved the evidence 
base. Ideally there is a need for an individual patient data meta-analysis, as well as 
prospective randomized studies similar to those undertaken in adults 21.
The finding that the PTIR is significantly associated with indication for treatment (Fontans 
or Non-Fontans) also corresponds with that of Moreau et al 26. However, our study showed 
that PTIR was also significantly associated with VKORC1 polymorphisms, with each 
additional variant allele associated with approximately 13% more time spent in range in the 
first six months. This contrasts with previous paediatric 25 and adult 37 studies, where those 
homozygous for VKORC1 variant alleles spent more treatment time above their INR 
therapeutic range (although not significantly in the paediatric study 25). In addition, Biss et 
al. 28 found no association between the CYP2C9 and VKORC1 genotypes and the proportion 
of INR values above the target range beyond the first month of therapy 25. This suggests that 
the adjustment of warfarin doses based on INR after the first month of therapy counteracted 
the influence of CYP2C9 and VKORC1 genotypes. A possible explanation is that carriers of 
VKORC1-1639 variant allele are more sensitive to warfarin and may have had more unstable 
INRs which may have led to more frequent monitoring by their POCT, and more frequent 
dose titration leading to a more stable INR over the duration of our follow up. However, we 
did not have the data to confirm this in our cohort. Nevertheless, it is consistent with the fact 
that POCT monitoring of INR is associated with safe anticoagulation 38. It may also explain 
some of the differences between our studies and those which have been published previously 
– only one of the previous studies 26 states that it included children who were monitored by 
POCT.
Clinically, the initiation of warfarin therapy is a time when large variations in the INR can 
occur as the stable dose has not yet been established. This replicates the previous data 
showing that possession of CYP2C9*2 alleles increase the likelihood of above therapeutic 
range INRs in the first week 28, although as this only explains 6.8% there are clearly other, 
more significant factors involved here. However, it does add to the evidence suggesting that 
inclusion of pharmacogenomic data in paediatric dosing algorithms could improve the 
management of children using warfarin.
This is also the first paediatric study to include minor bleeding complications, as we feel that 
INR variations are not necessarily associated with poor clinical outcomes. Heterozygotes for 
VKORC1-1639 were significantly associated with increased minor bleeding complications; 
however, unlike previous adult studies39, CYP2C9 variants were not. This may reflect the 
smaller sample size in our study. We believe these data also add to the clinical case for 
developing pharmacogenomic based dosing algorithms for children using warfarin, as it is 
the first evidence linking the lower dose required in children with VKORC1-1639 mutant 
alleles with the adverse effects of overtreatment with warfarin.
Although we recruited 100 children, analysis was limited to 97 to ensure identical ethnic 
origin, and we did not have any children homozygous for CYP2C9*3, limiting the analyses 
possible with these data. In addition, these data, although recorded systematically from a 
single site, in a prospective manner, by the team undertaking the POC testing, were collected 
retrospectively and so there were missing data that could not be determined. It was also not 
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possible to ascertain compliance with medication in this cohort, and this may explain a 
significant part of the currently unexplained variability. However, this is a closely monitored 
population through the POC testing system used, and regular education of the patients and 
family is undertaken, minimizing this potential limitation as much as possible.
In conclusion, we have added to the evidence showing that variant alleles in CYP2C9 and 
VKORC1 are important determinants of warfarin dose requirements and anticoagulation 
stability in children. However, as with other studies in children, this is based on a 
retrospective cohort, which may introduce bias into the associations. Our data also indicate 
that age may be important in determining the relative contribution of genetic and non-
genetic factors. Given all of these complexities, the development of dosing algorithms in 
children will be extremely complicated and will need to initially undertake an individual 
patient data meta-analysis as was undertaken in adults by the International Warfarin 
Pharmacogenetics Consortium 40. Furthermore, the dosing algorithms will have to be robust 
and take into account the pharmacokinetics of warfarin. The importance of dosing 
algorithms has been highlighted in two recent trials in adults where different results were 
obtained based on the dosing strategies utilized21, 41.
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Figure 1. Box and whisker plots showing the distribution of PTIR based on (a) target INR group, 
(b) indication treatment group, and (c) stratified by VKORC1 genotypes
Boxes represent 25th-75th percentile (interquartile range) of PTIR, whiskers represent 
5th-95th percentile, solid lines represent median dose. Open dots denote outliers (a value 
between 1.5 and 3 times the interquartile range away from the 25th or 75th percentile).
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Table 1
Summary of participant characteristics at the start of warfarin therapy and at the time stable dose was achieved
Variable
Start of therapy (n=97) Time of stable dose (n=85)*
Mean SD Missing Mean SD Missing
Age (decimal yrs)
# 2.3 (median) 4.2 (IQR) 0 5.7 (median) 8.0 (IQR) 0
Height (m) 0.94 0.28 26 1.06 0.28 40
Weight (kg) 15.7 14.5 12 20.6 15.7 35
BMI (kg.m−2)† 16.1 3.1 26 16.5 2.5 40
Albumin (g.L−1) 38.3 5.3 30 39.2 6.2 62
*
12 patients did not achieve stable dose during follow-up (see supplementary table 2)
#
Age distribution was skewed, hence median and IQR range given
†
BMI = body mass index
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Table 2
P values from tests of association of non-genetic variables with initial outcome measures
PTIR in 1st 6
months
INR exceeding target
range in week 1 (Y/N)
Stable dose
(mg/day)
Age 0.144 0.584 <0.001 *
Height 0.105 0.802 -
Weight 0.336 0.619 -
BMI 0.334 0.215 -
Albumin 0.982 0.897 -
Gender 0.468 0.173 0.351
INR group 0.004 * 0.657 0.015*
Indication (2 groups) 0.050 * 0.543 0.379
Indication (3 groups) 0.144 0.771 0.575
PTIR: Proportion of time spent in target INR range. 2 Groups: Patients were divided into non-Fontan and Fontan group. 3 Groups: patients were 
divided into non-Fontan cardiac, Fontan cardiac and non-cardiac. - Variable excluded due to high amount of missingness (>30%).
*
Variables with p < 0.10 were included as covariates in subsequent analyses of association
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Table 3
Individual SNP association analyses
Outcome SNP (assumption) p-value from LRT
Proportion of time in INR range (PTIR)
(adjusted for indication for treatment and
target INR group)
CYP2C9*2 (additive) 0.53
CYP2C9*3 (NA
†
) 0.95
VKORC1-1639 (additive) 0.001 *
INR above range in week 1
CYP2C9*2 (additive) 0.004 *
CYP2C9*3 (NA
†
) 0.800
VKORC1-1639 (additive) 0.020
Stable dose
(adjusted for age and target INR group)
CYP2C9*2 (additive) 0.008 *
CYP2C9*3 (NA
†
) 0.049
VKORC1-1639 (additive) 0.003 *
Haemorrhagic complications
CYP2C9*2 (additive) 0.423
CYP2C9*3 (NA
†
) 0.482
VKORC1-1639 (none) 0.006 *
FDR = false discovery rate; LRT = likelihood ratio test.
Full details of all modes of inheritance are shown in supplementary table
†
No mutant homozygotes so assumption regarding mode of inheritance irrelevant
*
Remains statistically significant following False discovery rate (FDR) adjustment
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Table 4
Final multiple regression models
Outcome Variables included
Adjusted/pseudo R2
Non-genetic variables Genetic variables All variables
PTIR
Indication for treatment
11.3% 9.5% 20.8%INR group
VKORC1-1639 (additive)
INR exceeding target range in week 1 CYP2C9*2 (additive) - 6.8% 6.8%
Stable dose
Age
29.2% 11.9% 41.4%
INR group
CYP2C9*2 (additive)
VKORC1-1639 (additive)
Haemorrhagic complications VKORC1-1639 (none) - 8.7% 8.7%
PTIR = Proportion of time spent in target INR range.
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